 RAHWAY, N.J.-- BUSINESS WIRE --Merck NYSE: MRK, known as MSD outside of the United States and Canada, today announced the presentation of findings from clinical trials and real-world studies at the upcoming 64th American Society of Hematology ASH Annual Meeting from Dec. 10-13, 2022, in New Orleans, Louisiana and virtually. New and updated data for KEYTRUDA, Mercks anti-PD-1 therapy, as well as from the companys investigational medicines favezelimab anti-LAG-3 antibody, zilovertamab vedotin antibody-drug conjugate targeting receptor tyrosine kinase-like orphan receptor 1 ROR1, and nemtabrutinib reversible, non-covalent Brutons tyrosine kinase BTK inhibitor will be featured in nearly 40 abstracts. 